Nifty

:

25227.35

Sensex

:

82327.05

-58.00 (-0.23%)
-173.77 (-0.21%)

Login

Nifty
Sensex

:
:

25227.35
82327.05

-58.00 (-0.23%)
-173.77 (-0.21%)

Aarti Pharmalabs Ltd.

Pharmaceuticals & Drugs

Rating :

60/99

BSE: 543748 | NSE: AARTIPHARM

Watchlist

NSE BSE

831.40

10-Oct-2025

Open
High
Low
Previous Close

834.75
834.75
826.6
834.75

Volume
Traded Value (lacs)
52 Week High
52 Week Low

66243
54952471.05
971
557.05

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

7,546.34
28.32
5

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

7,934.04
0.60%
3.70

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

-
-
2.83

EBITDA CAGR (%)

10 Years
5 Years
3 Years

-
-
6.31

PAT CAGR (%)

10 Years
5 Years
3 Years

-
-
12.08

P:E (Median)

8 Years
5 Years
3 Years

-
-
-

P:BV (Average)

8 Years
5 Years
3 Years

-
-
-

EV:EBITDA (Average)

8 Years
5 Years
3 Years

-
-
-

Earnings Forecasts:

(Updated: 11-10-2025)

Description 2024 2025 2026 2027
Adj EPS 30.06 33.79 39.35
P/E Ratio 27.66 24.60 21.13
Revenue 2086 2274.75 2763.2
EBITDA 464.37 523.85 615.25
Net Income 272.4 306 356.7
ROA 9.93
P/B Ratio 3.79 3.33 2.92
ROE 14.54 13.5 13.75
FCFF -87.84
FCFF Yield -1.12
Net Debt 356.91
BVPS 219.55 249.7 284.5

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Jun 25 Jun 24 Var% Mar 25 Mar 24 Var% Dec 24 Dec 23 Var% Sep 24 Sep 23 Var%
Net Sales 375.31 393.49 -4.62% 529.62 414.82 27.67% 470.95 373.03 26.25% 377.29 356.14 5.94%
Expenses 280.18 309.83 -9.57% 386.50 307.47 25.70% 355.96 284.76 25.00% 292.52 282.34 3.61%
EBITDA 95.13 83.65 13.72% 143.13 107.34 33.34% 114.99 88.28 30.26% 84.77 73.80 14.86%
EBIDTM 25.35% 21.26% 27.02% 25.88% 24.42% 23.66% 22.47% 20.72%
Other Income 1.60 2.11 -24.17% -2.50 5.69 - 11.94 0.46 2,495.65% 2.95 0.00 0
Interest 6.80 4.25 60.00% 6.29 4.42 42.31% 9.70 4.36 122.48% 5.39 3.82 41.10%
Depreciation 22.76 18.29 24.44% 20.83 17.32 20.27% 21.04 16.94 24.20% 18.89 16.32 15.75%
PBT 67.17 63.23 6.23% 113.50 91.28 24.34% 96.18 67.44 42.62% 63.43 53.67 18.19%
Tax 15.95 16.08 -0.81% 24.66 28.26 -12.74% 22.66 19.25 17.71% 15.60 11.86 31.53%
PAT 51.22 47.14 8.66% 88.85 63.02 40.99% 73.52 48.19 52.56% 47.84 41.81 14.42%
PATM 13.65% 11.98% 16.78% 15.19% 15.61% 12.92% 12.68% 11.74%
EPS 5.65 5.20 8.65% 9.81 6.96 40.95% 8.12 5.32 52.63% 5.28 4.61 14.53%

Description Jun 25 Jun 24 Var% Mar 25 Mar 24 Var% Dec 24 Dec 23 Var% Sep 24 Sep 23 Var%
Net Sales 386.19 555.49 -30.48% 563.78 505.77 11.47% 537.78 448.69 19.86% 458.03 439.80 4.15%
Expenses 290.95 459.03 -36.62% 418.15 388.25 7.70% 409.17 353.01 15.91% 364.35 351.81 3.56%
EBITDA 95.24 96.46 -1.26% 145.63 117.51 23.93% 128.61 95.68 34.42% 93.67 87.99 6.46%
EBIDTM 24.66% 17.36% 25.83% 23.23% 23.91% 21.32% 20.45% 20.01%
Other Income 1.60 2.22 -27.93% -1.61 2.03 - 5.03 1.39 261.87% 4.48 0.99 352.53%
Interest 6.80 4.83 40.79% 6.58 4.68 40.60% 9.97 4.48 122.54% 5.51 3.89 41.65%
Depreciation 22.79 20.17 12.99% 22.82 19.12 19.35% 23.04 18.77 22.75% 20.88 18.14 15.10%
PBT 67.25 73.68 -8.73% 114.62 95.75 19.71% 100.63 73.82 36.32% 71.77 66.95 7.20%
Tax 15.95 18.22 -12.46% 26.28 30.50 -13.84% 26.64 21.05 26.56% 17.14 15.14 13.21%
PAT 51.30 55.45 -7.48% 88.34 65.25 35.39% 73.99 52.76 40.24% 54.62 51.80 5.44%
PATM 13.28% 9.98% 15.67% 12.90% 13.76% 11.76% 11.93% 11.78%
EPS 5.46 6.12 -10.78% 9.75 7.20 35.42% 8.16 5.82 40.21% 6.03 5.72 5.42%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated

Right to Left

Description TTM Mar 25 Mar 24 Mar 23 Mar 22
Net Sales 1,753.17 1,771.35 1,502.13 1,511.25 941.02 Net Sales Growth 14.03% 17.92% -0.60% 60.60% Cost Of Goods Sold 835.85 879.26 751.97 817.93 451.66 Gross Profit 917.32 892.09 750.16 693.32 489.36 GP Margin 52.32% 50.36% 49.94% 45.88% 52.00% Total Expenditure 1,315.16 1,344.81 1,155.97 1,202.91 761.24 Power & Fuel Cost - 80.19 82.92 74.22 69.73 % Of Sales - 4.53% 5.52% 4.91% 7.41% Employee Cost - 139.82 120.15 113.92 79.98 % Of Sales - 7.89% 8.00% 7.54% 8.50% Manufacturing Exp. - 133.24 98.22 96.20 132.62 % Of Sales - 7.52% 6.54% 6.37% 14.09% General & Admin Exp. - 43.88 37.35 29.30 6.98 % Of Sales - 2.48% 2.49% 1.94% 0.74% Selling & Distn. Exp. - 51.97 49.19 48.54 20.25 % Of Sales - 2.93% 3.27% 3.21% 2.15% Miscellaneous Exp. - 16.45 16.17 22.80 0.01 % Of Sales - 0.93% 1.08% 1.51% 0.00% EBITDA 438.02 426.54 346.16 308.34 179.78 EBITDA Margin 24.98% 24.08% 23.04% 20.40% 19.10% Other Income 13.99 14.49 11.01 1.28 2.51 Interest 28.18 25.63 16.63 20.49 11.34 Depreciation 83.52 79.06 66.01 55.77 37.23 PBT 340.28 336.34 274.52 233.36 133.73 Tax 78.87 78.99 73.87 61.63 27.00 Tax Rate 23.18% 23.49% 26.91% 26.41% 20.19% PAT 261.43 257.35 200.65 171.73 106.73 PAT before Minority Interest 261.43 257.35 200.65 171.73 106.73 Minority Interest 0.00 0.00 0.00 0.00 0.00 PAT Margin 14.91% 14.53% 13.36% 11.36% 11.34% PAT Growth 30.61% 28.26% 16.84% 60.90% EPS 28.86 28.41 22.15 18.95 11.78

Description TTM Mar 25 Mar 24 Mar 23 Mar 22
Net Sales 1,945.78 2,115.07 1,852.61 1,945.23 1,199.94 Net Sales Growth -0.20% 14.17% -4.76% 62.11% Cost Of Goods Sold 959.05 1,127.88 1,020.71 1,169.76 637.67 Gross Profit 986.73 987.20 831.89 775.48 562.27 GP Margin 50.71% 46.67% 44.90% 39.87% 46.86% Total Expenditure 1,482.62 1,650.70 1,466.56 1,603.18 994.67 Power & Fuel Cost - 81.32 84.03 75.10 90.00 % Of Sales - 3.84% 4.54% 3.86% 7.50% Employee Cost - 148.65 128.03 121.32 85.20 % Of Sales - 7.03% 6.91% 6.24% 7.10% Manufacturing Exp. - 141.94 105.52 98.78 145.95 % Of Sales - 6.71% 5.70% 5.08% 12.16% General & Admin Exp. - 49.08 40.51 30.20 8.13 % Of Sales - 2.32% 2.19% 1.55% 0.68% Selling & Distn. Exp. - 79.71 68.88 74.83 27.38 % Of Sales - 3.77% 3.72% 3.85% 2.28% Miscellaneous Exp. - 22.12 18.88 33.20 0.34 % Of Sales - 1.05% 1.02% 1.71% 0.03% EBITDA 463.15 464.37 386.05 342.05 205.27 EBITDA Margin 23.80% 21.96% 20.84% 17.58% 17.11% Other Income 9.50 10.12 4.90 2.32 4.19 Interest 28.86 26.90 17.21 21.05 11.96 Depreciation 89.53 86.90 73.24 62.54 42.12 PBT 354.27 360.69 300.49 260.77 155.38 Tax 86.01 88.28 83.59 67.28 33.13 Tax Rate 24.28% 24.48% 27.82% 25.80% 21.32% PAT 268.25 272.40 216.90 193.49 122.25 PAT before Minority Interest 268.25 272.40 216.90 193.49 122.25 Minority Interest 0.00 0.00 0.00 0.00 0.00 PAT Margin 13.79% 12.88% 11.71% 9.95% 10.19% PAT Growth 19.08% 25.59% 12.10% 58.27% EPS 29.61 30.07 23.94 21.36 13.49

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated

Right to Left

Description Mar 25 Mar 24 Mar 23 Mar 22
Shareholder's Funds 1,843.87 1,621.46 1,438.58 1,284.28 Share Capital 45.32 45.31 45.31 0.25 Total Reserves 1,796.82 1,575.92 1,393.27 1,238.71 Non-Current Liabilities 257.40 119.87 74.04 60.88 Secured Loans 103.56 0.00 0.00 0.00 Unsecured Loans 0.00 0.00 0.00 0.00 Long Term Provisions 7.09 5.28 4.66 0.00 Current Liabilities 622.33 555.58 463.75 481.67 Trade Payables 248.97 254.79 212.50 131.61 Other Current Liabilities 71.52 43.76 36.20 8.98 Short Term Borrowings 291.30 250.80 206.71 324.62 Short Term Provisions 10.54 6.24 8.33 16.46 Total Liabilities 2,723.60 2,296.91 1,976.37 1,826.83 Net Block 1,059.32 953.33 848.40 701.12 Gross Block 1,653.44 1,472.15 1,303.76 1,100.71 Accumulated Depreciation 594.12 518.82 455.37 399.59 Non Current Assets 1,510.81 1,162.85 1,010.15 936.56 Capital Work in Progress 368.70 136.92 101.90 187.37 Non Current Investment 41.15 43.83 42.67 39.87 Long Term Loans & Adv. 41.63 28.77 17.18 8.21 Other Non Current Assets 0.00 0.00 0.00 0.00 Current Assets 1,212.80 1,134.06 966.22 890.27 Current Investments 15.88 17.83 12.81 0.00 Inventories 544.22 582.15 537.68 444.38 Sundry Debtors 552.59 448.82 371.67 304.22 Cash & Bank 3.52 4.43 0.37 56.50 Other Current Assets 96.58 13.97 7.18 11.53 Short Term Loans & Adv. 83.01 66.86 36.51 73.65 Net Current Assets 590.47 578.48 502.47 408.60 Total Assets 2,723.61 2,296.91 1,976.37 1,826.83

Description Mar 25 Mar 24 Mar 23 Mar 22
Shareholder's Funds 1,989.91 1,757.04 1,558.49 1,386.48 Share Capital 45.32 45.31 45.31 0.25 Total Reserves 1,942.86 1,711.50 1,513.17 1,340.91 Non-Current Liabilities 259.45 130.68 84.91 72.76 Secured Loans 103.56 0.04 0.18 0.55 Unsecured Loans 0.00 0.00 0.00 0.00 Long Term Provisions 8.12 6.06 5.36 0.00 Current Liabilities 657.05 694.39 600.62 580.67 Trade Payables 277.83 378.32 339.50 214.59 Other Current Liabilities 73.54 45.84 38.33 11.89 Short Term Borrowings 292.80 263.92 213.78 337.73 Short Term Provisions 12.88 6.31 9.01 16.46 Total Liabilities 2,906.41 2,582.11 2,244.02 2,039.91 Net Block 1,136.57 1,033.33 925.84 782.09 Gross Block 1,795.66 1,609.29 1,431.25 1,225.00 Accumulated Depreciation 659.09 575.96 505.41 442.90 Non Current Assets 1,584.24 1,236.46 1,081.02 1,011.75 Capital Work in Progress 374.35 136.92 101.87 187.37 Non Current Investment 29.24 36.78 35.52 32.23 Long Term Loans & Adv. 44.08 29.44 17.78 10.07 Other Non Current Assets 0.00 0.00 0.00 0.00 Current Assets 1,322.17 1,345.64 1,163.01 1,028.15 Current Investments 47.56 70.39 50.99 0.00 Inventories 587.58 642.86 602.04 475.45 Sundry Debtors 575.40 519.34 450.10 376.66 Cash & Bank 8.65 24.07 12.19 83.27 Other Current Assets 102.98 17.01 7.70 10.74 Short Term Loans & Adv. 87.28 71.97 39.98 82.03 Net Current Assets 665.12 651.25 562.38 447.48 Total Assets 2,906.41 2,582.10 2,244.03 2,039.90

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated

Right to Left

Description Mar 25 Mar 24 Mar 23 Mar 22
Cash From Operating Activity 340.01 183.69 215.88 -64.84 PBT 336.34 274.52 233.36 133.73 Adjustment 109.05 80.71 76.87 46.08 Changes in Working Capital -46.88 -124.55 -37.61 -229.65 Cash after chg. in Working capital 398.51 230.68 272.61 -49.84 Interest Paid 0.00 0.00 0.00 0.00 Tax Paid -58.50 -46.99 -56.73 -15.00 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 Cash From Investing Activity -419.80 -184.40 -115.55 -133.54 Net Fixed Assets -413.07 -203.41 -117.58 Net Investments 4.63 -6.18 -15.61 Others -11.36 25.19 17.64 Cash from Financing Activity 78.63 4.40 -156.53 254.63 Net Cash Inflow / Outflow -1.16 3.70 -56.20 56.25 Opening Cash & Equivalents 4.00 0.30 56.50 0.25 Closing Cash & Equivalent 2.84 4.00 0.30 56.50

Description Mar 25 Mar 24 Mar 23 Mar 22
Cash From Operating Activity 331.56 216.35 250.12 -43.70 PBT 360.69 300.49 260.77 155.38 Adjustment 121.47 94.65 83.35 52.41 Changes in Working Capital -86.07 -121.85 -31.63 -230.36 Cash after chg. in Working capital 396.09 273.29 312.50 -22.57 Interest Paid 0.00 0.00 0.00 0.00 Tax Paid -64.53 -56.94 -62.38 -21.13 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 Cash From Investing Activity -413.90 -214.56 -157.80 -138.74 Net Fixed Assets -413.07 -203.41 -117.58 Net Investments 4.63 -6.18 -15.61 Others -5.46 -4.97 -24.61 Cash from Financing Activity 65.44 9.72 -163.46 260.38 Net Cash Inflow / Outflow -16.90 11.51 -71.15 77.94 Opening Cash & Equivalents 23.63 12.12 83.27 5.33 Closing Cash & Equivalent 6.73 23.63 12.12 83.27

Financial Ratios

Standalone /

Consolidated

Right to Left

Description Mar 25 Mar 24 Mar 23 Mar 22
Book Value (Rs.) 203.25 178.89 158.74 49558.52 ROA 10.25% 9.39% 9.03% 11.68% ROE 14.86% 13.11% 12.83% 17.23% ROCE 17.61% 16.55% 15.60% 18.03% Fixed Asset Turnover 1.13 1.08 1.26 0.85 Receivable days 103.17 99.68 81.62 118.00 Inventory Days 116.05 136.05 118.59 172.36 Payable days 104.56 113.41 76.78 53.18 Cash Conversion Cycle 114.66 122.33 123.44 237.18 Total Debt/Equity 0.21 0.15 0.14 0.26 Interest Cover 14.12 17.50 12.39 12.79

Description Mar 25 Mar 24 Mar 23 Mar 22
Book Value (Rs.) 219.36 193.85 171.97 53646.60 ROA 9.93% 8.99% 9.03% 11.98% ROE 14.55% 13.08% 13.35% 18.23% ROCE 17.59% 16.75% 16.11% 19.40% Fixed Asset Turnover 1.24 1.22 1.46 0.98 Receivable days 94.46 95.50 77.57 114.57 Inventory Days 106.17 122.63 101.09 144.62 Payable days 106.17 128.34 86.45 61.41 Cash Conversion Cycle 94.46 89.79 92.21 197.78 Total Debt/Equity 0.20 0.15 0.14 0.25 Interest Cover 14.41 18.46 13.39 13.99

Top Investors:

life insurance corporation of india

ntasain discovery master fund

nishant pradip shah

investor education and protection fund (iepf)

Annual Reports:

News Update:

Aarti Pharmalabs inaugurates phase 1 of greenfield manufacturing facility in Gujarat
3rd Sep 2025, 16:42 PM

The company has successfully obtained all the necessary permissions and approvals to start the facility
Read More
Aarti Pharmalabs - Quarterly Results
12th Aug 2025, 19:24 PM

Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.

Feedback